https://www.selleckchem.com/pr....oducts/acalabrutinib
02-0.05). High versus low dose PCC did not affect hemostasis or thrombosis. Patients with ICH had higher mortality rates (22%, CI 0.13-0.32). Heterogeneity was significant (Ι 50% with p 0.05) for all pooled proportional outcomes. The quality of evidence was low given that included studies were not randomized or controlled. Our study demonstrates the efficacy and safety of the off label use of 4F PCC in major bleeding associated with factor Xa inhibitors. Our data require further validation with future randomized clinica
Respect!
Kommentar
Delen
